Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases.
Phosphorus-32, employed as the orthophosphate or polyphosphate, can reduce or relieve the pain of osteoblastic metastases without serious hematologic toxicity, especially if used as a single injection. Uptake of this beta-emitter by osteoblastic-reactive bone and possibly by tumor and other cells can lead to pain reduction and often to cell killing. Efficacy has been demonstrated for the treatment of pain in 84% of 322 breast cancer patients and 77% of 444 prostate cancer patients found in a review of the literature. These results match those of the newer radiopharmaceuticals currently under investigation.
Silberstein
E B
EB
University of Cincinnati Medical Center, OH 45267.
Elgazzar
A H
AH
Kapilivsky
A
A
D001859:Bone Neoplasms / Q000503:physiopathology / Q000556:secondary*; D006801:Humans; D010146:Pain / Q000209:etiology / Q000532:radiotherapy*; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*
D010761:Phosphorus Radioisotopes